HAART

Bioxytran Gets Broad Patent Coverage on 60+ Viruses

Retrieved on: 
Tuesday, October 24, 2023
RSV, Patent, Epstein–Barr virus, Viral, HAART, Reading, Lectin, Nipa, Hepatitis C, Measles, Protease, Pathology, HIV, Intellectual property, Virus, Cell, Research, Drug development, COVID-19, Mumps, MOA, Virology, Rubella, Simplex, Shingles, Drug resistance, Movement, Enzyme inhibitor, Plasma protein binding, DNA, Vaccine, Pharmaceutical industry, H1N1, Galectin

BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced that the U.S Patent and Trademark Office (USPTO) has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections. The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.

Key Points: 
  • The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.
  • This patent represents what we believe is a new direction in the evolution of antiviral therapies that originally started during the HIV epidemic.
  • This pending patent with its broad claims also shows the Company is well-positioned with respect to its intellectual property portfolio.
  • This patent covers some of the largest indications in virology and includes viruses like COVID-19, influenza, herpes, Epstein-Barr, shingles, hepatitis C, measles, mumps, and rubella.

CytoDyn Cancels Webcast and Live Q/A Scheduled for Today

Retrieved on: 
Thursday, January 13, 2022
Oncology, AIDS, Health, Infectious Diseases, Pharmaceutical, Biotechnology, Biomarker, Calendar, Forward-looking statement, HIV, Patient, Fatty liver disease, HIV/AIDS, Human, Vaccine, Inflammation, Clinical trial, Government budget balance, Fast Track, OTCQB, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Form 10-K, BLA, COVID-19, Social conditions in Honduras, ME/CFS, Partnership, SARS, Optimism, Cirrhosis, XV, Triple-negative breast cancer, CCR5, Refusal, Standard of care, Common, NASH, Securities and Exchange Commission (Philippines), Sleep, PASC, Fatigue, HAART, Myalgia, Degenerative disease, Company, Viral load, Food, Fibrosis, NAFLD, Biologics license application, FDA, 100,000, Cell, Compliance, Security (finance), Immunoglobulin G, Risk, Pharmaceutical industry, R5, Leronlimab

CytoDyn Inc. (OTCQB: CYDY) (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has canceled its webcast scheduled for today, Thursday, January 13, 2022 and will provide an update at a future date.

Key Points: 
  • CytoDyn Inc. (OTCQB: CYDY) (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has canceled its webcast scheduled for today, Thursday, January 13, 2022 and will provide an update at a future date.
  • Leronlimab does not work on other strains of HIV (for example X4), however, R5 is the most dominant strain of HIV.
  • About 30 to 40 percent of adults in the U.S. live with NAFLD, and 3 to 12 percent of adults in the U.S. live with NASH.
  • CytoDyn also completed a Phase 2b/3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients.

CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO

Retrieved on: 
Wednesday, December 22, 2021
Biotechnology, AIDS, Professional Services, Courts, Health, Pharmaceutical, Oncology, Infectious Diseases, Legal, Public Policy, Government, Clinical Trials, Contract research organization, HIV/AIDS, 100,000, Triple-negative breast cancer, Douglas v. U.S. District Court ex rel Talk America, Cell, Common, HAART, Fast Track, Immunoglobulin G, Forward-looking statement, COVID-19, Fatty liver disease, Sleep, HIV, Fatigue, Food, Clinical trial, Vaccine, Standard of care, U.S. Securities and Exchange Commission, Inflammation, Patient, ME/CFS, Compliance, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Social conditions in Honduras, Cirrhosis, Company, Court, Fibrosis, Biomarker, District court, Degenerative disease, PASC, Human, CCR5, OTCQB, Optimism, NSF International, Myalgia, SARS, Government budget balance, Security (finance), Calendar, Viral load, District, Form 10-K, NASH, XV, BLA, Risk, NAFLD, FDA, Partnership, Pharmaceutical industry, Leronlimab, R5, Leronlimab, CytoDyn, LERONLIMAB, CYTODYN

Over the past eight years, Amarex provided clinical trial management services to CytoDyn and managed numerous clinical trials.

Key Points: 
  • Over the past eight years, Amarex provided clinical trial management services to CytoDyn and managed numerous clinical trials.
  • Specifically, the Courts injunction requires Amarex to provide CytoDyn full access to the electronic data capture (EDC) and all related data.
  • Additionally, the order is subject to the Company posting a $6.5 million bond no later than January 14, 2022.
  • Nader Pourhassan, Ph.D., CytoDyns President and Chief Executive Officer, commented, We are pleased with the Courts ruling and are focused on the positive momentum of our pipeline.

Internationally Recognized Dr. Peter Centre in Vancouver Goes Live with VitalHub’s eMAR

Retrieved on: 
Wednesday, December 8, 2021
VHI, Company, Ministry of Children, Community and Social Services, Adoption of electronic medical records in U.S. hospitals, EMR, GLOBE, Technology, Nursing, Growth, Clinical professor, EHR, Center, Phrase, Bed, Failure, Software, Home health, Evaluation, Research, Electronic health record, Patient, HAART, United States Department of Health and Human Services, Case management, Narcotic, ADT, THE, TSX, HIV/AIDS, HIV, Corporation, Mental health, MAR, Human services, Social services, Communication, Regional health authority, Emar, Documentation, Diagnosis, Nursing care plan, Risk, Community, Admission, HIR, Roger Hawkins (drummer), Medical device, Hospital, Risk management

The Dr. Peter Centre uses B Care to support the provision of services to the facilitys inpatient and very large outpatient population in various programs.

Key Points: 
  • The Dr. Peter Centre uses B Care to support the provision of services to the facilitys inpatient and very large outpatient population in various programs.
  • VitalHubs eMOC and eMAR modules are being utilized for both inpatient (residential) and community (day health) programs.
  • ABOUT THE DR. PETER CENTRE: Since 1997, the Dr. Peter Centre managesday health programs, a 24-hour licensed care residence, and an enhanced supportive housing program.
  • The Dr. Peter Centre is a leader in HIV/AIDS care, particularly for individuals facing social barriers and multiple medical conditions.

CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA

Retrieved on: 
Thursday, October 28, 2021
Fatty liver disease, Vaccine, Partnership, THE, BLA, U.S. Securities and Exchange Commission, SARS, PASC, Triple-negative breast cancer, Government budget balance, Clinical trial, Biomarker, COVID-19, Inflammation, GLOBE, Sleep, HIV, Cros, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIV/AIDS, BLUE, Human, Cirrhosis, Security (finance), HAART, Food, Company, Biologics license application, ME/CFS, Degenerative disease, Social conditions in Honduras, Viral load, Fibrosis, Immunoglobulin G, Compliance, DRS, Common, Fast Track, Myalgia, Calendar, Suite, SEC, OTCQB, Refusal, Optimism, CMC, Fatigue, XV, Risk, Annual general meeting, Main Street, Cancer, NAFLD, CCR5, Patient, FDA, 100,000, Forward-looking statement, Standard of care, Cell, Form 10-K, NASH, Pharmaceutical industry

VANCOUVER, Washington, Oct. 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the U.S. Food and Drug Administration (“FDA”) has accepted the Company’s revised “Rolling Review” timeline for the Company’s upcoming resubmission of its Biologics License Application (“BLA”) for leronlimab as a combination therapy for highly treatment experienced HIV patients. Rolling review enables a drug company to submit completed sections of its BLA for contemporaneous review by the FDA, rather than waiting until every section of the BLA is complete before the entire application is reviewed. The Company also announced that it expects the non-clinical and CMC sections of the BLA to be resubmitted to the FDA in November and, as previously disclosed, the clinical section of the BLA is anticipated to be completed and resubmitted during the first quarter of calendar 2022.

Key Points: 
  • Rolling review enables a drug company to submit completed sections of its BLA for contemporaneous review by the FDA, rather than waiting until every section of the BLA is complete before the entire application is reviewed.
  • Nader Pourhassan, Ph.D., CytoDyns President and Chief Executive Officer, commented, We are very pleased with the continued rolling review status of our upcoming BLA resubmission, which is expected to reduce the overall review time.
  • Recknor and Ray, have remained so dedicated over the past several months to successful resubmission of our BLA, deserve kudos for this confirmation.
  • The U.S. Food and Drug Administration (FDA) granted CytoDyn Fast Track designation to explore two potential indications using leronlimab to treat Human Immunodeficiency Virus (HIV) and metastatic cancer.

CytoDyn Announces Treatment of First Patient in Pivotal Phase 3 Trial for Critically Ill COVID-19 Patients in Brazil

Retrieved on: 
Monday, October 25, 2021
Fatty liver disease, Vaccine, Partnership, THE, BLA, U.S. Securities and Exchange Commission, SARS, PASC, Triple-negative breast cancer, Government budget balance, Clinical trial, Biomarker, COVID-19, Inflammation, Sleep, HIV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIV/AIDS, BLUE, Human, Cirrhosis, Security (finance), HAART, Food, Company, Biologics license application, ME/CFS, Degenerative disease, Social conditions in Honduras, Viral load, Fibrosis, Immunoglobulin G, Compliance, Common, Fast Track, Myalgia, Calendar, Suite, SEC, Refusal, Optimism, CD16, Fatigue, XV, Risk, Annual general meeting, Main Street, NAFLD, CCR5, Patient, FDA, 100,000, Professional, Forward-looking statement, Standard of care, Cell, Form 10-K, NASH, Pharmaceutical industry

VANCOUVER, Washington, Oct. 25, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the treatment of the first patient in its pivotal Phase 3 trial (CD16) in Brazil for critically ill COVID-19 patients. An interim analysis will be conducted 28 days following the enrollment of 127 patients. On September 9, 2021, the Company announced the treatment of the first patient in its other pivotal Phase 3 trial in Brazil (CD17). An interim analysis for this trial will be conducted 28 days after 245 patients have been enrolled.

Key Points: 
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • CytoDyn is also conducting a Phase 2 clinical trial for NASH to evaluate the effect of leronlimab on liver steatosis and fibrosis.
  • CytoDyn successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected patients who were heavily treatment-experienced individuals with limited treatment options.
  • CytoDyn also completed a Phase 2b/3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients.

CytoDyn to Present at Emerging Growth Conference on October 13 Followed by Live Q/A

Retrieved on: 
Thursday, October 7, 2021
Biologics license application, BLA, NAFLD, Name, Myalgia, HIV, Human, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Main Street, NASH, Company, 100,000, Inflammation, Calendar, Optimism, Fibrosis, Form 10-K, PASC, COVID-19, Standard of care, FDA, U.S. Securities and Exchange Commission, HIV/AIDS, Fatty liver disease, Clinical trial, Risk, Cirrhosis, Suite, Annual general meeting, ME/CFS, Food and Drug Administration Amendments Act of 2007, Viral load, SARS, Fast Track, Food, Cell, Refusal, Annual report, Common, Vaccine, Sleep, HAART, Triple-negative breast cancer, Forward-looking statement, Fatigue, Government budget balance, THE, Immunoglobulin G, XV, Security (finance), Degenerative disease, Compliance, Partnership, Patient, Biomarker, Social conditions in Honduras, CCR5, Pharmaceutical industry

The conference sponsor provides corporate visibility services to CytoDyn for a fee.

Key Points: 
  • The conference sponsor provides corporate visibility services to CytoDyn for a fee.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • It binds to CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.
  • Leronlimab does not work on other strains of HIV (for example X4), however, R5 is the most dominant strain of HIV.

CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A

Retrieved on: 
Monday, September 27, 2021
Biotechnology, Pharmaceutical, AIDS, Oncology, Health, FDA, Infectious Diseases, Clinical Trials, Standard of care, Fatty liver disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immunoglobulin G, HIV/AIDS, Degenerative disease, Myalgia, Cirrhosis, Cell, HAART, File, SEC, HIV, Food, Vaccine, Compliance, Triple-negative breast cancer, Common, Sleep, Annual general meeting, Optimism, NAFLD, NASH, Government budget balance, XV, Clinical trial, Partnership, BLA, Fatigue, Annual report, Inflammation, Social conditions in Honduras, U.S. Securities and Exchange Commission, FDA, Biologics license application, Fast Track, THE, Company, Refusal, CCR5, Human, ME/CFS, Forward-looking statement, Fibrosis, Viral load, Name, 100,000, Suite, Risk, Security (finance), Patient, Beneficial ownership, Biomarker, Form 10-K, Main Street, PASC, COVID-19, SARS, Pharmaceutical industry, Leronlimab, CytoDyn, LERONLIMAB, CYTODYN

This is a livestream presentation, and a link will also be posted on CytoDyns website approximately 48 hours after the presentation.

Key Points: 
  • This is a livestream presentation, and a link will also be posted on CytoDyns website approximately 48 hours after the presentation.
  • The conference sponsor provides corporate visibility services to CytoDyn for a fee.
  • It binds to CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.
  • Leronlimab does not work on other strains of HIV (for example X4), however, R5 is the most dominant strain of HIV.

CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A

Retrieved on: 
Monday, September 13, 2021

The conference sponsor provides corporate visibility services to CytoDyn for a fee.

Key Points: 
  • The conference sponsor provides corporate visibility services to CytoDyn for a fee.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • It binds to CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.
  • Leronlimab does not work on other strains of HIV (for example X4), however, R5 is the most dominant strain of HIV.

BioStable Science & Engineering Initiates European Commercialization of the HAART™ 200 Aortic Annuloplasty Device

Retrieved on: 
Friday, August 6, 2021
Medical Devices, Health, Surgery, General Health, Cardiology, Biotechnology, HAART, Medical University of Silesia, CEO, Wrocław Medical University, Dissection, Engineering, Technology, Patient, Congenital heart defect, Bicuspid aortic valve, Almost, Aortic insufficiency, Science, PMID, Surgeon, Aortic aneurysm, HJ, Medical school, Instrumentation

Professor Jasinski commented, The HAART 200 Aortic Annuloplasty Device is a great addition to our aortic valve repair tool kit providing a new option for the most common congenital heart defect, bicuspid aortic valve disease.

Key Points: 
  • Professor Jasinski commented, The HAART 200 Aortic Annuloplasty Device is a great addition to our aortic valve repair tool kit providing a new option for the most common congenital heart defect, bicuspid aortic valve disease.
  • Our experience with the HAART 300 Aortic Annuloplasty Devices in trileaflet aortic valve repair has shown us how the devices simplify aortic valve repair and at the same time provide durable annuloplasty.
  • John Wheeler, President and CEO, concluded by saying, BioStable is very pleased to initiate commercialization of the HAART 200 Aortic Annuloplasty Device alongside the HAART 300 Devices.
  • With the commercial availability of the HAART 200 and HAART 300 Aortic Annuloplasty Devices, BioStable can offer surgeons within the European a comprehensive portfolio of aortic valve repair solutions that addresses all forms of aortic valve insufficiency.